Quantitative in vitro and in vivo pharmacological profile of CE-178253, a potent and selective cannabinoid type 1 (CB1) Receptor Antagonist

BMC Pharmacology

Volumn 10, Issue , 2010, Pages

  Hadcock, John R ^a   Carpino, Philip A ^a   Iredale, Philip A ^a   Dow, Robert L ^a   Gautreau, Denise ^a   Thiede, Lucinda ^a   Kelly Sullivan, Dawn ^a   Lizano, Jeffrey S ^a   Liu, Xingrong ^b   Van Deusen, Jeffrey ^a   Ward, Karen M ^a   O'Connor, Rebecca E ^a   Black, Shawn C ^c   Griffith, David A ^a   Scott, Dennis O ^a  

^a PFIZER INC   (United States)

^b Roche   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (2 CHLOROPHENYL) 8 (4 CHLOROPHENYL) 2 METHYLPYRAZOLO[1,5 A][1,3,5]TRIAZIN 4 YL] 3 ETHYLAMINOAZETIDINE 3 CARBOXYLIC ACID HYDROCHLORIDE; CANNABINOID 1 RECEPTOR AGONIST; CARBOHYDRATE; CE 178253; FAT; UNCLASSIFIED DRUG; ANOREXIGENIC AGENT; AZETIDINE DERIVATIVE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CE-178253; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CALORIC INTAKE; CALORIMETRY; CLINICAL TRIAL; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; ENERGY EXPENDITURE; EX VIVO STUDY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OBESITY; OXIDATION; QUANTITATIVE ANALYSIS; RAT; RECEPTOR OCCUPANCY; RESPIRATORY QUOTIENT; WEIGHT REDUCTION; ANIMAL; BINDING COMPETITION; BLOOD; BRAIN; C57BL MOUSE; CELL LINE; DOSE RESPONSE; DRUG ANTAGONISM; EATING; ENERGY METABOLISM; GENETICS; METABOLISM; OXYGEN CONSUMPTION; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ANIMALS; APPETITE DEPRESSANTS; AZETIDINES; BINDING, COMPETITIVE; BRAIN; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENERGY METABOLISM; HUMANS; MALE; MICE; MICE, INBRED C57BL; OBESITY; OXYGEN CONSUMPTION; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; TRIAZINES; WEIGHT LOSS;

EID: 77955528474     PISSN: None     EISSN: 14712210     Source Type: Journal    
DOI: 10.1186/1471-2210-10-9     Document Type: Article

References (35)

1. Howlett AC, Barth F, Bonner TI, Cabral, Casellas G, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, Mechoulam R, Pertwee RG. International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 2002, 54(2):161-202. 10.1124/pr.54.2.161, 12037135.
2. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (Wash DC) 1997, 258:1946-1949.
3. Mechoulam R, Ben-Shabat S, Hanus L, Ligumsky M, Kaminski NE, Schatz AR, Gopher A, Almog S, Martin BR, Compton DR, Pertwee RG, Griffin G, Bayewitch M, Barg J, Vogel Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50(1):83-90. 10.1016/0006-2952(95)00109-D, 7605349.
4. Hanus L, Abu-Lafi S, Fride E, Breuer A, Vogel Z, Shalev DE, Kustanovich I, Mechoulam R. 2-arachindoyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 2001, 98:3662-3665. 10.1073/pnas.061029898, 31108, 11259648.
5. Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid. J Pharmacol Exp Therap 1994, 270:219-27.
6. Arnone M, Maruani J, Chaperon F, Thiebot M-H, Poncelet M, Soubrie P, Le Fur G. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, 132(1):104-106. 10.1007/s002130050326, 9272766.
7. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, Fezza F, Miura G, Palmiter RD, Sugiura T, Kunos G. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410(6830):822-825. 10.1038/35071088, 11298451.
8. de Kloet AD, Woods SC. Minireview: Endocannabinoids and Their Receptors as Targets for Obesity Therapy. Endocrinol 2009, 50(6):2531-2536.
9. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, Batkai S. Endocannabinoids and the Control of Energy Homeostasis. J Biol Chem 2008, 283(48):33021-33025. 10.1074/jbc.R800012200, 2586261, 18694938.
10. Pagotto U, Marsicano G, Cota D, Lutz B, Pasquali R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73-100. 10.1210/er.2005-0009, 16306385.
11. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, Caput D, Ferrara P, Soubrié P, Brelière JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994, 350:240-244. 10.1016/0014-5793(94)00773-X, 8070571.
12. Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, Shen CP, Lao J, Xiao JC, Shearman LP, Stribling DS, Rosko K, Strack A, Marsh DJ, Feng Y, Kumar S, Samuel K, Yin W, Van der Ploeg LH, Goulet MT, Hagmann WK. Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 2006, 49:7584-7587. 10.1021/jm060996+, 17181138.
13. Griffith DA, Hadcock JR, Black SC, Iredale PA, Carpino PA, DaSilva-Jardine P, Day R, DiBrino J, Dow RL, Landis MS, O'Connor RE, Scott DO. Discovery of 1-[9-(4-Chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-Yl]-4-ethylaminopiperidine-4-carboxylic Acid Amine Hydrochloride (CP-945,598), a Novel, Potent and Selective Cannabinoid CB1 Receptor Antagonist. J Med Chem 2009, 52:234-237. 10.1021/jm8012932, 19102698.
14. Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, Papa SM. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 2007, 323(1):318-326. 10.1124/jpet.107.125666, 17630359.
15. Brandt TA, Caron S, Damon DB, DiBrino J, Ghosh A, Griffith DA, Kedia S, Ragan JA, Rose PR, Vanderplas BC, Wei L. Development of two synthetic routes to CE-178253, a CB1 antagonist for the treatment of obesity. Tetrahedron 2009, 65(16):3292-3304.
16. Bass R, Strnad J, Price LA, Pausch MH, Hadcock JR. Identification and characterization of novel somatostatin antagonists. Mol Pharm 1996, 50:709-715.
17. Maurer TS, Debartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug metabolism and disposition: the biological fate of chemicals 2005, 33(1):175-81. 10.1124/dmd.104.001222, 15502010.
18. Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR-141716 is an inverse agonist at the human cannabinoid CB1 receptor. Eur J Pharmacol 1997, 334:R1-R2. 10.1016/S0014-2999(97)01160-6, 9346339.
19. Roth RA. The enigmatic pharmacology of GPR55. Trends Pharmacol Sci 2005, 30(3):156-163.
20. De Petrocellis L, Bisogno T, Maccarrone M, Davis JB, Finazzi-Agro A, Di Marzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001, 276(16):12856-63. 10.1074/jbc.M008555200, 11278420.
21. De Petrocellis L, Starowicz K, Moriello AS, Vivese MM, Orlando P, Di Marzo V. Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Experimental Cell Research 2007, 313(9):1911-20. 10.1016/j.yexcr.2007.01.008, 17428469.
22. Kalvass JC, Maurer SM. Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery. Biopharmaceutics & Drug Disposition 2002, 23(8):327-338.
23. Maurer TS, DeBartolo DB, Tess DA, Scott DO. Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 2005, 33:175-81. 10.1124/dmd.104.001222, 15502010.
24. Read KD, Braggio S. Assessing brain free fraction in early drug discovery. Expert Opinion on Drug Metabolism & Toxicology 2010, 6(3):337-344.
25. Kirkham TC. Endocannabinoids in the regulation of appetite and body weight. Behav Pharmacol 2005, 16:297-313. 10.1097/00008877-200509000-00004, 16148436.
26. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, Roche R, Maj M, Pagotto U, Monteleone P, Di Marzo V. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006, 91:3171-3180. 10.1210/jc.2005-2679, 16684820.
27. Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775. 10.1001/jama.295.7.761, 16478899.
28. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002, 136:550-557. 10.1038/sj.bjp.0704767, 1573386, 12055133.
29. Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL. Appetite suppression and weight loss after the cannabinoid antagonist SR141716. Life Sci 1998, 63(8):PL113-PL117. 10.1016/S0024-3205(98)00322-1, 9718088.
30. Ravinet C, Arnone M, Delgorge C, Gonalons N. Keane, Peter, Maffrand, J-P, Soubrie, Philippe. Anti-obesity effect of SR-141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284(2):R345-353.
31. Vickers SP, Webster LJ, Wyatt A, Dourish CT, Kennett GA. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 2003, 167(1):103-111.
32. Hildebrandt AL, Kelly-Sullivan DM, Black SC. Antiobesity effects of chronic cannabinoid CB1 receptor antagonist treatment in diet-induced obese mice. Eur J Pharmacol 2003, 462(1-3):125-132. 10.1016/S0014-2999(03)01343-8, 12591104.
33. Fong TM, Guan X-M, Marsh DJ, Shen CP, Stribling DS, Rosko KM, Lao J, Yu H, Feng Y, Xiao JC, Van der Ploeg LHT, Goulet MK, Hagmann WK, Lin LS, Lanza TJ, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Francis B, Strack AM, MacIntyre DE. Shearman, LP.Antiobesity Efficacy of a Novel Cannabinoid-1 Receptor Inverse Agonist, N-[(1S,2S)-3-(4-Chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), in Rodents. J.Pharmacol Exp Ther 2007, 321:1013-1022. 10.1124/jpet.106.118737, 17327489.
34. Kunos G, Osei-Hyiaman D, Bátkai S, Sharkey KA, Makriyannis A. Should peripheral CB1 cannabinoid receptors be selectively targeted for therapeutic gain?. Trends Pharmacol Sci 2009, 30(1):1-7. 10.1016/j.tips.2008.10.001, 2748782, 19042036.
35. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, Fekete C, Reizes O, Rohner-Jeanrenaud F, Tschöp MH. Peripheral, but Not Central, CB1 Antagonism Provides Food Intake-Independent Metabolic Benefits in Diet-Induced Obese Rats. Diabetes 2008, 57:2977-2991. 10.2337/db08-0161, 2570394, 18716045.